1
|
Dreher N, Layton TM, Parker BA, Shibley WP, Acerbi I, Wallace AM, Blair S, Pierce JP, Glantz S, Guydish J, Hiatt R, van 't Veer L, Esserman L. Abstract P4-10-03: Tobacco exposure and breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-10-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Smoking is a known risk factor for various types of cancer, and breast cancer patients who smoke are known to have higher breast cancer mortality. However, few studies have found an association between smoking and breast cancer incidence or tumor biology. The Athena Breast Health Network distributes an intake questionnaire at the UCSF and UCSD breast care centers which can be used to investigate links between tobacco exposure and the characteristics of incident breast cancer.
Methods: Intake questionnaires were distributed to all new patients at the UCSF and UCSD breast care centers from December 2012 to May 2018. Patients who completed the questionnaire with a known diagnosis of breast cancer were compared to those without in a case-control study. Breast cancer diagnoses were determined by ICD9 diagnosis codes from the patients' medical records. The association of smoking and breast cancer prevalence and biology was analyzed using generalized linear models and Fisher tests in R.
Results: Of the 7727 patients who completed the Athena intake questionnaire at UCSF and UCSD, 5499 consented to have their data used for research. A first analysis was conducted on 4175 UCSF patients alone: 2186 of the UCSF patients who had completed the questionnaire had a documented breast cancer diagnosis, vs 1989 with no known diagnosis at the time of this analysis. 1096 of the 4175 UCSF patients reported having ever smoked, including 73 who had accrued 30 or more pack years. Complete pathology data was available for 1120 cancer patients. Controlling for age, more patients with invasive breast cancer reported having ever smoked, with an odd's ratio (OR) of 2.32 (p = .0043). By including DCIS, the OR drops slightly to 2.26 (p = .0058). Taking alcohol consumption into account as a confounder lowered the OR to 2.19 (p = .0454). Overall, the risk of breast cancer increases with each additional pack year (OR = 1.08, p = .0211), independent of age. There are no significant differences in tumor biology for any smoking group.
Conclusions: A history of smoking is associated with an increased risk of developing breast cancer and is directly related to cumulative pack years exposure. This association should be further validated in cohort studies.
Citation Format: Dreher N, Layton TM, Parker BA, Shibley WP, Acerbi I, Wallace AM, Blair S, Pierce JP, Glantz S, Guydish J, Hiatt R, van 't Veer L, Esserman L, Athena Breast Health Network Investigators and Advocate Partners. Tobacco exposure and breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-10-03.
Collapse
Affiliation(s)
- N Dreher
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA
| | - TM Layton
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA
| | - BA Parker
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA
| | - WP Shibley
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA
| | - I Acerbi
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA
| | - AM Wallace
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA
| | - S Blair
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA
| | - JP Pierce
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA
| | - S Glantz
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA
| | - J Guydish
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA
| | - R Hiatt
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA
| | - L van 't Veer
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA
| | - L Esserman
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA
| | | |
Collapse
|
2
|
Acerbi I, Shieh Y, Madlensky L, Tice J, Ziv E, Eklund M, Blanco A, DeRosa D, Tong B, Goodman D, Nassereddine L, Anderson N, Harvey H, Layton T, Park HL, Petruse A, Stewart S, Wernisch J, Risty L, Koenig B, Sarrafan S, Firouzian R, Kaplan C, Hiatt R, Parker BA, Wenger N, Lee V, Heditsian D, Brain S, Stover Fiscalini A, Borowsky AD, Anton-Culver H, Naeim A, Kaster A, Talley M, van 't Veer LJ, LaCroix A, Esserman LJ. Abstract OT2-08-01: Personalized breast cancer screening in a population based study: Women Informed to Screen Depending On Measures of risk (WISDOM). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-ot2-08-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: WISDOM is a 100,000 healthy women preference-tolerant, pragmatic study comparing annual to personalized risk-based breast screening. The novelty of WISDOM personalized screening is the integration of previously validated genetic and clinical risk factors (age, family history, breast biopsy results, ethnicity, mammographic density) into a single risk assessment model that directs the starting age, timing, and frequency of screening. The goal of WISDOM is to determine if personalized screening, compared to annual screening, is as safe, less morbid, enables prevention, and is preferred by women. The study is registered on ClinicalTrials.gov, NCT02620852.
Methods: Women aged 40-74 years with no history of breast cancer or DCIS, and no previous double mastectomy can join the study online at wisdomstudy.org. Participants can elect randomization or self-select a study arm, and provide electronic consent and Release for Medical Information using DocuSign. For all participants, 5-year risk of developing breast cancer is calculated according to the Breast Cancer Screening Consortium (BCSC) model. Participants in the personalized arm undergo panel-based mutation testing, and their 5-year risk is calculated using the BCSC score combined with a Polygenic Risk Score (BCSC-PRS) that includes 75 single nucleotide polymorphisms (SNPs, increase to 229) known to increase breast cancer risk. SNPs and mutations (BRCA1, BRCA2, TP53, PTEN, STK11, CDH1, ATM, PALB2, and CHEK2) are assessed by saliva-based testing through Color Genomics. 5-year risk level thresholds are used to stratify for low-, moderate- and high risk. Risk stratification determines age to start, stop, and frequency of screening.
Enrollment: As of July 2018, the WISDOM study is open to all eligible women in California, North Dakota, South Dakota, Minnesota and Iowa. To date, 23,329 eligible women have registered and 14,393 women have consented to participate in the trial. We analyzed 3,255 participants who have completed risk assessment in the personalized arm. The median age was 56 years. 82% were Caucasian, 1% African-American, and 6% Asian. 9% self-reported as Hispanic. We are partnering with health insurers and self-insured companies using coverage with evidence progression. To strengthen generalizability, we are expanding to other states. WISDOM enrollment will continue past 2019.
Feasibility: To evaluate the addition of PRS, we used paired statistical tests (McNemar) to compare the distributions of BCSC, and BCSC-PRS risk estimates around low-risk (<1.3%), and very-high risk (>6%) thresholds, the latter corresponding to 5-year risk of a BRCA mutation carrier. The median 5-year risk was 1.5% (IQR 1.0-2.1%) using the BCSC model, and 1.4% (IQR 0.8-2.5%) using the BCSC-PRS model. The BCSC-PRS model classified more women into the low (<1%) and very high (≥6%) risk categories compared to the BCSC model (p < 0.001).
Conclusions: Our findings demonstrate that incorporating genetic variants into a validated clinical model is feasible and impacts risk classification compared to a model without genetic risk factors. Results at 5 years will reveal if this classification improves healthcare value by reducing screen volumes and costs without jeopardizing outcomes.
Citation Format: Acerbi I, Shieh Y, Madlensky L, Tice J, Ziv E, Eklund M, Blanco A, DeRosa D, Tong B, Goodman D, Nassereddine L, Anderson N, Harvey H, Layton T, Park HL, Petruse A, Stewart S, Wernisch J, Risty L, Koenig B, Sarrafan S, Firouzian R, Kaplan C, Hiatt R, Parker BA, Wenger N, Lee V, Heditsian D, Brain S, Stover Fiscalini A, Borowsky AD, Anton-Culver H, Naeim A, Kaster A, Talley M, van 't Veer LJ, LaCroix A, Wisdom Study and Athena Breast Health Network Investigators and Advocate Partners, Esserman LJ. Personalized breast cancer screening in a population based study: Women Informed to Screen Depending On Measures of risk (WISDOM) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT2-08-01.
Collapse
Affiliation(s)
- I Acerbi
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - Y Shieh
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - L Madlensky
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - J Tice
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - E Ziv
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - M Eklund
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - A Blanco
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - D DeRosa
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - B Tong
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - D Goodman
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - L Nassereddine
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - N Anderson
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - H Harvey
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - T Layton
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - HL Park
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - A Petruse
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - S Stewart
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - J Wernisch
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - L Risty
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - B Koenig
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - S Sarrafan
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - R Firouzian
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - C Kaplan
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - R Hiatt
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - BA Parker
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - N Wenger
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - V Lee
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - D Heditsian
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - S Brain
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - A Stover Fiscalini
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - AD Borowsky
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - H Anton-Culver
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - A Naeim
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - A Kaster
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - M Talley
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - LJ van 't Veer
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - A LaCroix
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - LJ Esserman
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | | |
Collapse
|
3
|
Hasan MK, Tripple V, Widhopf GF, Yu J, Zhang S, Parker BA, Kipps TJ. Abstract P1-01-05: Wnt5a induces ROR1 to associate with cortactin, which undergoes tyrosine phosphorylation, and enhances migration of breast cancer cells. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p1-01-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: ROR1is an evolutionarily conserved, oncoembryonic surface-antigen expressed in breast cancer. Previously, we found that ROR1 can serve as a receptor for Wnt5a, which can induce non-canonical Wnt signaling that enhances cancer-cell migration. Recently we found that Wnt5a could induce ROR1 to complex with a cytoskeletal protein designated HS1, which recruited ARHGEF1, enhanced activation of RhoA, and promoted leukemia-cell migration. These effects of Wnt5a on CLL cells could be inhibited by cirmtuzumab, a humanized, high-affinity monoclonal antibody (mAb) specific for ROR1. As expression of HS1 is limited to hematopoietic cells we examined breast cancer cell lines and primary breast cancer cells for expression of cortactin. Cortactin (also called EMS1), is a cytoskeletal protein, which is homologous in structure and function to HS1 and is broadly expressed in human cancers, including breast cancer.
Methods: We performed immunoprecipitation studies using high-affinity mAb to ROR1 or cortactin and immunoblot analysis to examine for the association of ROR1 with cortactin and tyrosine phosphorylation of cortactin at Y421. We also assessed the expression levels of cortactin, ROR1, and ARHGEF1, in the MCF7 breast cancer cell line and in breast-cancer patient-derived xenografts (PDX). We also generated MCF7-ROR1 cells, which were stably transfected to express ROR1 or various mutant forms of ROR1 generated to study the structure-function requirements for effective ROR1-cortactin interactions.
Results: We found that ROR1 associates with cortactin in freshly-isolated breast cancer PDX tumors or in PDX cells cultured with exogenous Wnt5a. We corroborated these results in breast cancer cell line MCF7-ROR1 cells, which were transfected to express ROR1 and found to migrate more effectively than the parental MCF7 lacking expression of ROR1. Wnt5a also induced cortactin tyrosine phosphorylation at Y421, recruitment of ARHGEF1, and activation of RhoA, which we found associated with enhanced breast-cancer cell migation. The capacity of Wnt5a to induce such changes could be blocked by treatment of the cells with cirmtuzumab. We generated truncated forms of ROR1 without a proline-rich domain (PRD) and found PRD was necessary for this association or Wnt5a-induced cortactin phosphorylation and enhanced cancer-cell migration. Accordingly, we introduced single amino-acid substitutions of proline (P) to alanine (A) in the ROR1-PRD at positions 784, 808, 826, or 841 in potential SH3-binding motifs. In contrast to wild-type ROR1, or other ROR1P→A mutants, ROR1P(841)A had impaired capacity to recruit cortactin and ARHGEF1 to ROR1 in response to Wnt5a. Moreover, Wnt5a could not induce cells expressing ROR1P(841)A to phosphorylate cortactin or activate ARHGEF1, and was unable to enhance the motility of the MCF7 cells transfected with this mutant form of ROR1.
Conclusions: Collectively, these studies indicate the capacity of cortactin to complex with ROR1 plays an important role in ROR1-dependent Wnt5a-enhanced breast cancer cell migration. These studies also demonstrate that cirmtuzumab can inhibit the formation of cortactin-ROR1 complexes, cortactin phosphorylation, and cancer-cell migration, and metastasis.
Citation Format: Hasan MK, Tripple V, Widhopf II GF, Yu J, Zhang S, Parker BA, Kipps TJ. Wnt5a induces ROR1 to associate with cortactin, which undergoes tyrosine phosphorylation, and enhances migration of breast cancer cells [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P1-01-05.
Collapse
Affiliation(s)
- MK Hasan
- Moores Cancer Center, University of California San Diego, La Jolla, CA
| | - V Tripple
- Moores Cancer Center, University of California San Diego, La Jolla, CA
| | - GF Widhopf
- Moores Cancer Center, University of California San Diego, La Jolla, CA
| | - J Yu
- Moores Cancer Center, University of California San Diego, La Jolla, CA
| | - S Zhang
- Moores Cancer Center, University of California San Diego, La Jolla, CA
| | - BA Parker
- Moores Cancer Center, University of California San Diego, La Jolla, CA
| | - TJ Kipps
- Moores Cancer Center, University of California San Diego, La Jolla, CA
| |
Collapse
|
4
|
Zhang S, Zhang H, Ghia EM, Liu G, Tripple V, Xu S, Cui B, Widhopf G, Yu J, Schwab R, Messer K, Parker BA, Kipps TJ. Abstract P1-09-07: Breast cancer initiating cells express functional ROR1, which can be targeted by cirmtuzumab to potentially mitigate the risk of relapse after therapy. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p1-09-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Although initially responsive to chemotherapy, patients with advanced breast cancer often relapse, generally with incurable metastatic disease. This may be due to a subpopulation of tumor cells, called cancer-initiating cells, or cancer stem cells (CSCs), which are relatively resistant to chemotherapy and have self-renewing and tumor-initiating capacities. Prior studies in our laboratory found that CSCs may express ROR1, an onco-embryonic, tyrosine-kinase-like orphan receptor, which we found could bind Wnt5a to activate non-canonical Wnt-signaling (Proc Nat Acad Sci USA 111:17266, 2014). Interrogation of the transcriptomes of breast-cancer cells obtained from patients before and after paclitaxel therapy revealed that chemotherapy treatment enhanced cancer-cell expression of ROR1, along with genes induced by activation of Rho-GTPases (e.g. RhoA, cdc42, and Rac1). We found that primary breast-cancer patient-derived xenografts with high-level expression of ROR1 were enriched for cells that had activated Rho-GTPases and stem-cell-like gene-expression signatures. Furthermore, we found that treatment of breast cancer cell lines with Wnt5a induced ROR1-dependent activation of Rho-GTPases andAKT and induced high-level protein expression of BMI1, also known as polycomb group RING finger protein 4 (PCGF4) or RING finger protein 51 (RNF51); Wnt5a also enhanced the capacity of breast cancer cell lines to form spheroids. All these effects could be inhibited by cirmtuzumab, a humanized high-affinity anti-ROR1 mAb, which can block Wnt5a signaling. We find that ROR1-positive breast cancer cells have a greater capacity to form spheroids or engraft immune-deficient mice than did ROR1-negative cancer cells isolated from the same PDX tumor. Treatment of immune-deficient mice bearing breast-cancer PDX with paclitaxel reduced tumor volumes but enhanced expression of ROR1 and other CSC markers, such as aldehyde dehydrogenase 1 (ALDH1). Moreover, the breast cancer cells surviving such paclitaxel treatment had increased activation of Rho-GTPases and AKT, and increased expression of BMI1, relative to that of breast cancer cells obtained from the same primary tumor prior to therapy. On the other hand, treatment of such mice with cirmtuzumab also reduced breast cancer PDX tumor volumes, but the remaining cells had reduced expression of ROR1 and CSC markers and had impaired capacity to re-engraft immune-deficient mice. Finally, therapy with cirmtuzumab and paclitaxel was more effective in eradicating breast-cancer PDX than treatment with either agent alone. Collectively, these findings support use of cirmtuzumab in combination with conventional anti-cancer drugs to improve the outcome of patients with advanced breast cancer.
Citation Format: Zhang S, Zhang H, Ghia EM, Liu G, Tripple V, Xu S, Cui B, Widhopf G, Yu J, Schwab R, Messer K, Parker BA, Kipps TJ. Breast cancer initiating cells express functional ROR1, which can be targeted by cirmtuzumab to potentially mitigate the risk of relapse after therapy [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P1-09-07.
Collapse
Affiliation(s)
- S Zhang
- Moores UCSD Cancer Center, University of California, San Diego, La Jolla, CA; Medical Cancer Research Center, School of Medicine, Shenzhen University, Shenzen, Guangdong, China; University of California, San Diego, La Jolla, CA
| | - H Zhang
- Moores UCSD Cancer Center, University of California, San Diego, La Jolla, CA; Medical Cancer Research Center, School of Medicine, Shenzhen University, Shenzen, Guangdong, China; University of California, San Diego, La Jolla, CA
| | - EM Ghia
- Moores UCSD Cancer Center, University of California, San Diego, La Jolla, CA; Medical Cancer Research Center, School of Medicine, Shenzhen University, Shenzen, Guangdong, China; University of California, San Diego, La Jolla, CA
| | - G Liu
- Moores UCSD Cancer Center, University of California, San Diego, La Jolla, CA; Medical Cancer Research Center, School of Medicine, Shenzhen University, Shenzen, Guangdong, China; University of California, San Diego, La Jolla, CA
| | - V Tripple
- Moores UCSD Cancer Center, University of California, San Diego, La Jolla, CA; Medical Cancer Research Center, School of Medicine, Shenzhen University, Shenzen, Guangdong, China; University of California, San Diego, La Jolla, CA
| | - S Xu
- Moores UCSD Cancer Center, University of California, San Diego, La Jolla, CA; Medical Cancer Research Center, School of Medicine, Shenzhen University, Shenzen, Guangdong, China; University of California, San Diego, La Jolla, CA
| | - B Cui
- Moores UCSD Cancer Center, University of California, San Diego, La Jolla, CA; Medical Cancer Research Center, School of Medicine, Shenzhen University, Shenzen, Guangdong, China; University of California, San Diego, La Jolla, CA
| | - G Widhopf
- Moores UCSD Cancer Center, University of California, San Diego, La Jolla, CA; Medical Cancer Research Center, School of Medicine, Shenzhen University, Shenzen, Guangdong, China; University of California, San Diego, La Jolla, CA
| | - J Yu
- Moores UCSD Cancer Center, University of California, San Diego, La Jolla, CA; Medical Cancer Research Center, School of Medicine, Shenzhen University, Shenzen, Guangdong, China; University of California, San Diego, La Jolla, CA
| | - R Schwab
- Moores UCSD Cancer Center, University of California, San Diego, La Jolla, CA; Medical Cancer Research Center, School of Medicine, Shenzhen University, Shenzen, Guangdong, China; University of California, San Diego, La Jolla, CA
| | - K Messer
- Moores UCSD Cancer Center, University of California, San Diego, La Jolla, CA; Medical Cancer Research Center, School of Medicine, Shenzhen University, Shenzen, Guangdong, China; University of California, San Diego, La Jolla, CA
| | - BA Parker
- Moores UCSD Cancer Center, University of California, San Diego, La Jolla, CA; Medical Cancer Research Center, School of Medicine, Shenzhen University, Shenzen, Guangdong, China; University of California, San Diego, La Jolla, CA
| | - TJ Kipps
- Moores UCSD Cancer Center, University of California, San Diego, La Jolla, CA; Medical Cancer Research Center, School of Medicine, Shenzhen University, Shenzen, Guangdong, China; University of California, San Diego, La Jolla, CA
| |
Collapse
|
5
|
Shatsky RA, Parker BA, Schwab R, Helsten T, Boles SG, Subramanian R, Piccioni D, Kurzrock R. Abstract P1-07-15: Detection of molecular alterations in breast cancer through next generation sequencing of both tumor tissue and circulating tumor DNA: The UC San Diego Moores Cancer Center experience. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p1-07-15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Next generation sequencing (NGS) analysis of actionable molecular alterations has the potential to guide cancer treatment, especially for patients with advanced cancer who have progressed on standard treatment. In this study, we analyzed tumor biopsies and peripheral blood from 62 patients with advanced breast cancer by two different NGS clinical-grade assays for molecular alterations in tumor tissue or in circulating tumor DNA (ctDNA). We used these results to determine if these specimens have potentially “actionable” alterations that could guide cancer therapy.
Methods: From 2014 to 2016, 62 patients with advanced breast cancer had plasma sent for ctDNA analysis (Guardant360 assay; 54 to 70 genes) Thirty-eight of these patients (61%) also had tumor biopsies evaluated by NGS (FoundationOne®; 182 to 315 genes). Alterations were defined as mutations, insertions, deletions, truncations, or rearrangements or amplifications/copy number variations. Patients that harbored multiple alterations in the same gene were not counted as having separate alterations; however, if a gene amplification and an alteration were found in the same gene these were counted as separate events. Variants of unknown significance (VUS) and synonymous mutations were excluded from both assays. Data were collected and analyzed according to a UCSD Institutional Review Board approved protocol.
Results: The median age of our patients at the time of ctDNA analysis was 55 years (range, 44 to 84 years); the median age at the time of tissue biopsy for NGS was 52 years (range, 39 to 82 years). One patient was male. The most common receptor status was estrogen receptor (ER) and progesterone receptor (PR) positive, human epidermal growth factor receptor 2 (HER2) non-amplified or negative (neg)(N=44; 71%), followed by triple negative breast cancer (ERnegPRnegHer2neg) (N=10, 16%), triple positive (N=6, 1%) and finally ERnegPRnegHER2positive (N=2, 0.03%). One patient of 38 (2%) had no tumor alteration detected and 19 of 62 had no ctDNA alterations (31%). In 38 breast cancer patients with tumor NGS results, alterations were detected in 79 unique genes, with the most frequent being TP53 (37% of patients), PIK3CA (24%) and GATA3 (24%) genes. In the 62 patients with ctDNA analysis, 31 unique genes had at least one alteration, with the most frequent being TP53 (36% of patients) and PIK3CA (23%) and EGFR amplification (11%) (GATA3 was not analyzed in the ctDNA assay). Both assays had a high rate of detection for potentially actionable mutations: 41 out of 62 patients (66%) by ctDNA and 34 out of 38 (89%) by tumor NGS. No two patients harbored identical genomic profiles by either tumor NGS or plasma ctDNA analysis except for 1 patient who had no alterations detected by either assay.
Conclusions: Plasma and tissue NGS analysis appear to be complementary assays that yield a high percentage of potentially actionable alterations in patients with advanced breast cancer. Studies of the clinical impact of NGS-guided therapy in breast cancer are warranted.
Citation Format: Shatsky RA, Parker BA, Schwab R, Helsten T, Boles SG, Subramanian R, Piccioni D, Kurzrock R. Detection of molecular alterations in breast cancer through next generation sequencing of both tumor tissue and circulating tumor DNA: The UC San Diego Moores Cancer Center experience [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-07-15.
Collapse
Affiliation(s)
- RA Shatsky
- University of California School of Medicine and Center for Personalized Medicine Moores Cancer Center, La Jolla, CA
| | - BA Parker
- University of California School of Medicine and Center for Personalized Medicine Moores Cancer Center, La Jolla, CA
| | - R Schwab
- University of California School of Medicine and Center for Personalized Medicine Moores Cancer Center, La Jolla, CA
| | - T Helsten
- University of California School of Medicine and Center for Personalized Medicine Moores Cancer Center, La Jolla, CA
| | - SG Boles
- University of California School of Medicine and Center for Personalized Medicine Moores Cancer Center, La Jolla, CA
| | - R Subramanian
- University of California School of Medicine and Center for Personalized Medicine Moores Cancer Center, La Jolla, CA
| | - D Piccioni
- University of California School of Medicine and Center for Personalized Medicine Moores Cancer Center, La Jolla, CA
| | - R Kurzrock
- University of California School of Medicine and Center for Personalized Medicine Moores Cancer Center, La Jolla, CA
| |
Collapse
|
6
|
de Vries Schultink AHM, Alexi X, van Werkhoven E, Madlensky L, Natarajan L, Flatt SW, Zwart W, Linn SC, Parker BA, Wu AHB, Pierce JP, Huitema ADR, Beijnen JH. An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome. Breast Cancer Res Treat 2016; 161:567-574. [PMID: 28005246 DOI: 10.1007/s10549-016-4083-6] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2016] [Accepted: 12/08/2016] [Indexed: 02/07/2023]
Abstract
PURPOSE Endoxifen concentrations have been associated with breast cancer recurrence in tamoxifen-treated patients. However, tamoxifen itself and other metabolites also show antiestrogenic anti-tumor activity. Therefore, the aim of this study was to develop a comprehensive Antiestrogenic Activity Score (AAS), which accounts for concentration and antiestrogenic activity of tamoxifen and three metabolites. An association between the AAS and recurrence-free survival was investigated and compared to a previously published threshold for endoxifen concentrations of 5.97 ng/mL. PATIENTS AND METHODS The antiestrogenic activities of tamoxifen, (Z)-endoxifen, (Z)-4-hydroxytamoxifen, and N-desmethyltamoxifen were determined in a cell proliferation assay. The AAS was determined by calculating the sum of each metabolite concentration multiplied by an IC50 ratio, relative to tamoxifen. The AAS was calculated for 1370 patients with estrogen receptor alpha (ERα)-positive breast cancer. An association between AAS and recurrence was investigated using Cox regression and compared with the 5.97 ng/mL endoxifen threshold using concordance indices. RESULTS An AAS threshold of 1798 was associated with recurrence-free survival, hazard ratio (HR) 0.67 (95% confidence interval (CI) 0.47-0.96), bias corrected after bootstrap HR 0.69 (95% CI 0.48-0.99). The concordance indices for AAS and endoxifen did not significantly differ; however, using the AAS threshold instead of endoxifen led to different dose recommendations for 5.2% of the patients. CONCLUSIONS Endoxifen concentrations can serve as a proxy for the antiestrogenic effect of tamoxifen and metabolites. However, for the aggregate effect of tamoxifen and three metabolites, defined by an integrative algorithm, a trend towards improving treatment is seen and moreover, is significantly associated with breast cancer recurrence.
Collapse
Affiliation(s)
- A H M de Vries Schultink
- Department of Pharmacy and Pharmacology, Antoni van Leeuwenhoek - The Netherlands Cancer Institute and MC Slotervaart, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands.
| | - X Alexi
- Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - E van Werkhoven
- Department of Biometrics, Antoni van Leeuwenhoek - The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - L Madlensky
- Moores Cancer Center, University of California San Diego, San Diego, CA, USA
| | - L Natarajan
- Moores Cancer Center, University of California San Diego, San Diego, CA, USA
| | - S W Flatt
- Moores Cancer Center, University of California San Diego, San Diego, CA, USA
| | - W Zwart
- Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - S C Linn
- Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.,Department of Pathology, University Medical Center, Utrecht, The Netherlands
| | - B A Parker
- Moores Cancer Center, University of California San Diego, San Diego, CA, USA
| | - A H B Wu
- Laboratory Medicine, University of California, San Francisco, CA, USA
| | - J P Pierce
- Moores Cancer Center, University of California San Diego, San Diego, CA, USA
| | - A D R Huitema
- Department of Pharmacy and Pharmacology, Antoni van Leeuwenhoek - The Netherlands Cancer Institute and MC Slotervaart, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands.,Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands
| | - J H Beijnen
- Department of Pharmacy and Pharmacology, Antoni van Leeuwenhoek - The Netherlands Cancer Institute and MC Slotervaart, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands.,Science Faculty, Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands
| |
Collapse
|
7
|
|
8
|
Parish A, Schwaederle M, Daniels G, Piccioni D, Fanta P, Schwab R, Shimabukuro K, Parker BA, Helsten T, Kurzrock R. Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics. Cell Cycle 2015; 14:2121-8. [PMID: 25950492 PMCID: PMC4614941 DOI: 10.1080/15384101.2015.1041691] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
Fibroblast growth factor ligands and receptors (FGF and FGFR) play critical roles in tumorigenesis, and several drugs have been developed to target them. We report the biologic correlates of FGF/FGFR abnormalities in diverse malignancies. The medical records of patients with cancers that underwent targeted next generation sequencing (182 or 236 cancer-related genes) were reviewed. The following FGF/FGFR genes were tested: FGF3, 4, 6, 7, 10, 12, 14, 19, 23 and FGFR1, 2, 3, and 4. Of 391 patients, 56 (14.3%) had aberrant FGF (N = 38, all amplifications) and/or FGFR (N = 22 including 5 mutations and one FGFR3-TACC3 fusion). FGF/FGFR aberrations were most frequent in breast cancers (26/81, 32.1%, p = 0.0003). In multivariate analysis, FGF/FGFR abnormalities were independently associated with CCND1/2, RICTOR, ZNF703, RPTOR, AKT2, and CDK8 alterations (all P < 0.02), as well as with an increased median number of alterations (P < 0.0001). FGF3, FGF4, FGF19 and CCND1 were co-amplified in 22 of 391 patients (5.6%, P < 0.0001), most likely because they co-localize on the same chromosomal region (11q13). There was no significant difference in time to metastasis or overall survival when comparing patients harboring FGF/FGFR alterations versus those not. Overall, FGF/FGFR was one of the most frequently aberrant pathways in our population comprising patients with diverse malignancies. These aberrations frequently co-exist with anomalies in a variety of other genes, suggesting that tailored combination therapy may be necessary in these patients.
Collapse
Affiliation(s)
- A Parish
- a Center for Personalized Cancer Therapy; University of California San Diego; Moores Cancer Center ; San Diego , CA , USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Parker BA, Schwab RB, Helsten TL, Sarah BG, Ojeda-Fournier H, Datnow B, Schwaederle MC, Coutinho AC, Kurzrock R. Abstract P4-04-15: UC San Diego molecular tumor board: Experience in breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p4-04-15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: To realize the promise of personalized medicine, it is important to build the infrastructure to match patients to the most promising therapies using evolving genomic information to inform clinical trial and treatment recommendations.
Methods: A molecular tumor board was established in December 2012 consisting of representatives of medical oncology, surgery, radiation, pathology, radiology, clinical genetics, molecular genetics and diagnostics, basic and translational science, and bioinformatics and pathway analysis. Patients with metastatic breast cancer signed consent for collection of data in a registry format related to clinical history, genomic analysis, treatment recommendations, and response. Tumor specimens from patients with metastatic breast cancer were subjected to a next generation sequencing diagnostic test (Foundation One™) in a CLIA-certified lab (Foundation Medicine) and analyzed for genomic alterations in a 182 gene panel or a 236 gene panel. Clinical cases and genomic alterations were discussed at Molecular Tumor Board where clinical trials and treatment recommendations were considered, with the final decision made by the treating oncologist.
Results: Genomic analyses of metastatic breast cancer specimens from 17 consented patients had at least one genomic alteration and no tumors had the same genomic alterations. 12/17 had ≥ 2 and 4/17 had 6 or 7 genomic alterations. The most common genomic alterations were in PIK3CA observed in tumors from 6/17 patients. 1/17 tumor specimens had only a single genomic alteration for which there are no current targeted drugs in clinical studies or available commercially (GATA3). Radiographic and/or tumor marker response have been observed to date in 3/4 heavily pretreated patients following treatment with a targeted therapy or a targeted therapy informed by the genomic data in combination with other drugs.
Conclusions: The strategy of matching targeted clinical trial and commercially available therapies to genomic alterations of tumor specimens from individual patients with metastatic breast cancer may offer promise to patients with advanced refractory disease. Biopsies of metastatic disease, genomic analysis in CLIA labs, establishment of molecular tumor boards, definition of “matched” versus “non-matched” therapies, capturing data in a registry to create a learning environment, and most importantly, availability of targeted therapies in clinical trials or commercially, are required for this individual patient strategy to inform current and future treatment options for much larger patient populations.
Funding from UC San Diego Moores Cancer Center MyAnswerToCancer philanthropic fund.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-04-15.
Collapse
Affiliation(s)
- BA Parker
- UC San Diego Moores Cancer Center, La Jolla, CA; UC San Diego School of Medicine, La Jolla, CA
| | - RB Schwab
- UC San Diego Moores Cancer Center, La Jolla, CA; UC San Diego School of Medicine, La Jolla, CA
| | - TL Helsten
- UC San Diego Moores Cancer Center, La Jolla, CA; UC San Diego School of Medicine, La Jolla, CA
| | - BG Sarah
- UC San Diego Moores Cancer Center, La Jolla, CA; UC San Diego School of Medicine, La Jolla, CA
| | - H Ojeda-Fournier
- UC San Diego Moores Cancer Center, La Jolla, CA; UC San Diego School of Medicine, La Jolla, CA
| | - B Datnow
- UC San Diego Moores Cancer Center, La Jolla, CA; UC San Diego School of Medicine, La Jolla, CA
| | - MC Schwaederle
- UC San Diego Moores Cancer Center, La Jolla, CA; UC San Diego School of Medicine, La Jolla, CA
| | - AC Coutinho
- UC San Diego Moores Cancer Center, La Jolla, CA; UC San Diego School of Medicine, La Jolla, CA
| | - R Kurzrock
- UC San Diego Moores Cancer Center, La Jolla, CA; UC San Diego School of Medicine, La Jolla, CA
| |
Collapse
|
10
|
|
11
|
Schwab RB, Bao L, Pu M, Crain B, Dai Y, Nazareth LV, Matsui H, Wallace AM, Hasteh F, Harismendy O, Frazer KA, Parker BA, Messer K. Abstract P2-06-01: Breast-to-breast metastasis can cause hormone-receptor positive/triple negative bilateral synchronous tumors. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p2-06-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Prior work suggests that synchronous bilateral breast cancers may be clonal, with one tumor a metastasis, although prior techniques lacked resolution to prove this relationship. We used deep whole exome and shallow whole genome sequencing to compare bilateral tumors in two cases. In both cases, tumors were invasive and node negative with one tumor ER+/PR+/HER2− (HR+) lobular and the other triple negative (TN) ductal. Case 1 is a 75-year-old African American woman and Case 2 a 70-year-old white woman. With 44 and 12 months of follow up, respectively, neither patient has recurred.
Methods: Agilent SureSelect All Exon 50Mb Target Enrichment Kits were used for exome capture. Paired-end sequencing was performed with 200 base pair reads on the Illumina HiSeq 2000. Sequencing depth was targeted to cover 80% of the genome at 100x for three tumors with 70% cellularity, 200x for one tumor with 40% cellularity and 30x for germline. Tumor and germline exome results were compared to identify high confidence somatic single nucleotide variants (HC SNV). HC SNV's were called using GATK and stringent custom filtering to avoid false positives resulting from unrecognized germline single nucleotide polymorphisms. For each tumor pair, we define a clonality likelihood score (CLS) as the ratio of the number of HC SNV called at the same site and with the same alternate base in both tumors, to the total number of sites with an HC SNV called in either tumor. For comparison we analyzed the called SNV data from The Cancer Genome Atlas (TCGA) for exome sequenced HR+ or TN breast cancers.
Results: In Case 1, of 102 HC SNVs called in either tumor, 82 were shared, for a CLS of 80.3%. Additionally, 11 shared SNVs were synonymous, consistent with clonality. Lastly the non-shared HC SNVs were asymmetrically found in the TN tumor, consistent with clonal evolution during metastasis. Copy number analysis (CNA) showed Case 1 to have a deletion in 6q, including the ESR1 gene, unique to the TN tumor.
To assess significance of the CLS, we found three primary/metastatic clonal pairs in the TCGA to serve as positive controls. To serve as negative controls, from 357 ER+ and 46 TN primary TCGA tumors, we formed a total of 16,422 independent ER+/TN pairs. For the 3 clonal TCGA pairs, the CLS values were 39.3%, 58.5% and 60.0%. Most of the independent TCGA pairs had a CLS of zero (98.5%), with a maximum CLS of 2.8%. As the CLS for Case 1 lies above maximum observed CLS among 16,422 independent tumor pairs, we reject the hypothesis that this tumor pair is independent, at p < 0.0001. For Case 2, of 222 HC SNV sites, 5 were shared for a CLS of 2.3%, consistent with independence.
Conclusion: Somatic single nucleotide mutations identified by exome sequencing found that the two tumors in Case 1 share >80% of SNVs, consistent with clonal evolution of metastasis. The two tumors from Case 2 have few shared SNVs, consistent with independent origin. CNA results were consistent. This is the first clonality analysis reported from deep sequencing of phenotypically discordant synchronous bilateral breast cancers, and demonstrates that next-generation sequencing can distinguish clonal from independent tumor pairs with high confidence.
Funding: The Breast Cancer Research Foundation
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P2-06-01.
Collapse
Affiliation(s)
- RB Schwab
- University of California, San Diego, La Jolla, CA; Rady Children's Hospital, Division of Genome Information Sciences, University of California, San Diego, La Jolla, CA
| | - L Bao
- University of California, San Diego, La Jolla, CA; Rady Children's Hospital, Division of Genome Information Sciences, University of California, San Diego, La Jolla, CA
| | - M Pu
- University of California, San Diego, La Jolla, CA; Rady Children's Hospital, Division of Genome Information Sciences, University of California, San Diego, La Jolla, CA
| | - B Crain
- University of California, San Diego, La Jolla, CA; Rady Children's Hospital, Division of Genome Information Sciences, University of California, San Diego, La Jolla, CA
| | - Y Dai
- University of California, San Diego, La Jolla, CA; Rady Children's Hospital, Division of Genome Information Sciences, University of California, San Diego, La Jolla, CA
| | - LV Nazareth
- University of California, San Diego, La Jolla, CA; Rady Children's Hospital, Division of Genome Information Sciences, University of California, San Diego, La Jolla, CA
| | - H Matsui
- University of California, San Diego, La Jolla, CA; Rady Children's Hospital, Division of Genome Information Sciences, University of California, San Diego, La Jolla, CA
| | - AM Wallace
- University of California, San Diego, La Jolla, CA; Rady Children's Hospital, Division of Genome Information Sciences, University of California, San Diego, La Jolla, CA
| | - F Hasteh
- University of California, San Diego, La Jolla, CA; Rady Children's Hospital, Division of Genome Information Sciences, University of California, San Diego, La Jolla, CA
| | - O Harismendy
- University of California, San Diego, La Jolla, CA; Rady Children's Hospital, Division of Genome Information Sciences, University of California, San Diego, La Jolla, CA
| | - KA Frazer
- University of California, San Diego, La Jolla, CA; Rady Children's Hospital, Division of Genome Information Sciences, University of California, San Diego, La Jolla, CA
| | - BA Parker
- University of California, San Diego, La Jolla, CA; Rady Children's Hospital, Division of Genome Information Sciences, University of California, San Diego, La Jolla, CA
| | - K Messer
- University of California, San Diego, La Jolla, CA; Rady Children's Hospital, Division of Genome Information Sciences, University of California, San Diego, La Jolla, CA
| |
Collapse
|
12
|
Ozanne EM, Crawford B, Petruse A, Madlensky L, Weiss L, Hogarth M, Wenger N, Goodman D, Park H, Anton-Culver H, Yasmeen S, Howell L, Ojeda H, Parker BA, Kaplan C, van't VL, Esserman L, Naeim A. Abstract P4-13-13: Risk Assessment and Personalized Decision Support: The University of California Athena Breast Health Network. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p4-13-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The Athena Breast Health Network is a University of California (UC) initiative to drive rapid innovation in patient-centered prevention, screening, and treatment of breast cancer. Athena is a collaborative of the five UC medical centers and UC Berkeley that integrates clinical care and research, rapidly mobilizing data and research to enable continuous improvement in patient care and outcomes. The first initiative of Athena was to implement risk assessment for women being screened for breast cancer and to offer tailored referrals for women found to be at increased risk of developing breast cancer.
Methods: Patients who enroll in Athena complete an electronic questionnaire to collect personal and family history data prior to their mammography screening visit. These data are used to generate multiple risk assessments using the NCCN and USPSTF guidelines, and BCRAT (Gail model). Data on established breast cancer risk factors such as chest wall radiation and history of hormone replacement therapy are also collected and used to identify women at potentially increased risk. Upon enrollment, women are given the opportunity to provide a blood or saliva sample for research purposes.
Women who meet Athena-defined criteria that identify them to be at increased risk receive a referral to a Breast Health Specialist (BHS). The BHS identifies individual patient needs for prevention and screening services, including genetic counseling and testing, provides referrals to a High Risk Breast Clinic or nurse practitioner, and conducts lifestyle modification counseling. BHS have special training in breast cancer risk assessment, and some are licensed genetic counselors. Primary care and/or referring providers are directly informed of risk assessment results through mailings or the electronic medical record.
Results: The recruitment goal enrollment for Athena is 150,000 and to date more than 17,000 women have been enrolled across the five centers. Of those enrolled, 32% indicated that they have a family history of cancer. 56% of the cohort consented to participate in research, and 40% provided a biospecimen for research purposes. Across the five centers, 32 educational outreach sessions about Athena were held, reaching approximately 375 providers.
Conclusion: Successful implementation of the Athena risk assessment and decision support process will enable the identification of high risk women who are most likely to benefit from tailored screening or risk reducing interventions and who otherwise may not have been referred for risk reducing measures. By identifying women at the highest risk and connecting them to screening and prevention resources, the Athena Breast Health Network aims to ultimately reduce the incidence of breast cancer in its participant cohort.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P4-13-13.
Collapse
Affiliation(s)
- EM Ozanne
- University of California, San Francisco, CA; University of California, Los Angeles, CA; University of California, San Diego, CA; Athena Program Management Office, San Francisco, CA; University of California, Davis, CA; University of California, Irvine, CA
| | - B Crawford
- University of California, San Francisco, CA; University of California, Los Angeles, CA; University of California, San Diego, CA; Athena Program Management Office, San Francisco, CA; University of California, Davis, CA; University of California, Irvine, CA
| | - A Petruse
- University of California, San Francisco, CA; University of California, Los Angeles, CA; University of California, San Diego, CA; Athena Program Management Office, San Francisco, CA; University of California, Davis, CA; University of California, Irvine, CA
| | - L Madlensky
- University of California, San Francisco, CA; University of California, Los Angeles, CA; University of California, San Diego, CA; Athena Program Management Office, San Francisco, CA; University of California, Davis, CA; University of California, Irvine, CA
| | - L Weiss
- University of California, San Francisco, CA; University of California, Los Angeles, CA; University of California, San Diego, CA; Athena Program Management Office, San Francisco, CA; University of California, Davis, CA; University of California, Irvine, CA
| | - M Hogarth
- University of California, San Francisco, CA; University of California, Los Angeles, CA; University of California, San Diego, CA; Athena Program Management Office, San Francisco, CA; University of California, Davis, CA; University of California, Irvine, CA
| | - N Wenger
- University of California, San Francisco, CA; University of California, Los Angeles, CA; University of California, San Diego, CA; Athena Program Management Office, San Francisco, CA; University of California, Davis, CA; University of California, Irvine, CA
| | - D Goodman
- University of California, San Francisco, CA; University of California, Los Angeles, CA; University of California, San Diego, CA; Athena Program Management Office, San Francisco, CA; University of California, Davis, CA; University of California, Irvine, CA
| | - H Park
- University of California, San Francisco, CA; University of California, Los Angeles, CA; University of California, San Diego, CA; Athena Program Management Office, San Francisco, CA; University of California, Davis, CA; University of California, Irvine, CA
| | - H Anton-Culver
- University of California, San Francisco, CA; University of California, Los Angeles, CA; University of California, San Diego, CA; Athena Program Management Office, San Francisco, CA; University of California, Davis, CA; University of California, Irvine, CA
| | - S Yasmeen
- University of California, San Francisco, CA; University of California, Los Angeles, CA; University of California, San Diego, CA; Athena Program Management Office, San Francisco, CA; University of California, Davis, CA; University of California, Irvine, CA
| | - L Howell
- University of California, San Francisco, CA; University of California, Los Angeles, CA; University of California, San Diego, CA; Athena Program Management Office, San Francisco, CA; University of California, Davis, CA; University of California, Irvine, CA
| | - H Ojeda
- University of California, San Francisco, CA; University of California, Los Angeles, CA; University of California, San Diego, CA; Athena Program Management Office, San Francisco, CA; University of California, Davis, CA; University of California, Irvine, CA
| | - BA Parker
- University of California, San Francisco, CA; University of California, Los Angeles, CA; University of California, San Diego, CA; Athena Program Management Office, San Francisco, CA; University of California, Davis, CA; University of California, Irvine, CA
| | - C Kaplan
- University of California, San Francisco, CA; University of California, Los Angeles, CA; University of California, San Diego, CA; Athena Program Management Office, San Francisco, CA; University of California, Davis, CA; University of California, Irvine, CA
| | - Veer L van't
- University of California, San Francisco, CA; University of California, Los Angeles, CA; University of California, San Diego, CA; Athena Program Management Office, San Francisco, CA; University of California, Davis, CA; University of California, Irvine, CA
| | - L Esserman
- University of California, San Francisco, CA; University of California, Los Angeles, CA; University of California, San Diego, CA; Athena Program Management Office, San Francisco, CA; University of California, Davis, CA; University of California, Irvine, CA
| | - A Naeim
- University of California, San Francisco, CA; University of California, Los Angeles, CA; University of California, San Diego, CA; Athena Program Management Office, San Francisco, CA; University of California, Davis, CA; University of California, Irvine, CA
| |
Collapse
|
13
|
Cadmus Bertram LA, Pierce JP, Patterson RE, Ojeda-Fournier H, Newman VA, Parker BA. Training overweight/obese older women at high risk for breast cancer to use web-based weight loss tools: The HELP pilot study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.27_suppl.233] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
233 Background: Excess weight is one of the few modifiable risk factors for incident breast cancer. Many programs can achieve a 7% weight loss but few can maintain it over time. Training women to use self-help resources over the internet has potential for reducing intervention costs and ensuring program maintenance. Methods: 50 overweight/obese (BMI≥27.5 kg/m2) women at increased risk of breast cancer (Gail score≥1.7) were identified from a mammography registry and enrolled in the HELP pilot study and randomized with 2:1 probability to a 12-week lifestyle intervention or a comparison group. Twelve telephone-based coaching calls trained participants to use a free, publicly available website to set goals and track performance for dietary intake and physical activity. The comparison group received information but no training. At baseline and 12 weeks, participants were weighed, fitted with an accelerometer for physical activity pattern, and completed questionnaires. Results: At baseline, participants were 60.9±0.79 years of age with a BMI of 33.1±0.60 kg/m2; 39% were daily internet users. Thirty-three were randomized to the intervention group with 91% completing follow-up. Fifty-four percent were able to use the website reliably and found it to be helpful, including 44% of previously nondaily internet users. At 12 weeks, intervention group participants who found the website helpful had lost 5.6±0.7 kg, or 6.7% of initial weight, intervention participants who did not find it helpful lost 0.8±0.9kg or 1.1% of initial weight and the comparison group gained 1.0±0.94 kg (89% follow-up) The between-group difference weight change was 4.2 kg (p<.0001). 74% of intervention group participants lost weight, compared to only 34% of women assigned to the comparison group. Conclusions: A 12-session telephone coaching program to train women to use publicly available web-based weight loss programs effectively achieved a large short-term weight loss among the majority of participants. Further follow-up is needed to identify how well the initial weight loss is maintained without further intervention assistance.
Collapse
Affiliation(s)
| | - J. P. Pierce
- University of California, San Diego Moores Cancer Center, La Jolla, CA
| | - R. E. Patterson
- University of California, San Diego Moores Cancer Center, La Jolla, CA
| | - H. Ojeda-Fournier
- University of California, San Diego Moores Cancer Center, La Jolla, CA
| | - V. A. Newman
- University of California, San Diego Moores Cancer Center, La Jolla, CA
| | - B. A. Parker
- University of California, San Diego Moores Cancer Center, La Jolla, CA
| |
Collapse
|
14
|
Cadmus Bertram LA, Pierce JP, Patterson RE, Ojeda-Fournier H, Parker BA. Training overweight/obese older women at high risk for breast cancer to use web-based weight loss tools: The HELP pilot study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e11128] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
15
|
Erickson KD, Pierce JP, Patterson RE, Reid TR, Natarajan L, Flatt S, Parker BA, Heath D. Type II diabetes and breast cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.1552] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
16
|
Madlensky L, Wasserman L, Parker BA, Pierce JP. The importance of updating the family history of breast cancer survivors. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-1097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #1097
BACKGROUND: The cancer family history is the most important tool in identifying women who may be at high risk of having the hereditary breast-ovarian cancer syndrome (HBOCS) caused by mutations in the BRCA1 and BRCA2 genes. While many breast cancer patients may be asked about their family history at the time of their initial diagnosis, it is not known how many women initially classified as low risk of HBOCS become high risk of HBOCS over time, as new cancers are diagnosed in their relatives.
 PURPOSE: 1)To determine how the prevalence of "high risk" cancer family histories changes over time in cancer patients, and; 2) To determine how many breast cancer survivors at high risk for HBOCS self-report having had genetic testing for BRCA1/2.
 METHODS: Breast cancer survivors in the Women's Healthy Eating and Living (WHEL) study provided detailed family history data at baseline and again at study closure. The Myriad prevalence tables were used to categorize survivors as "high risk" of HBOCS if their risk of having a mutation in BRCA1/2 was 10% or greater.
 RESULTS: At baseline, 8.2% of 2508 survivors were classified as high risk. At follow-up (avg. 7.5 years later), an additional 5.8% of women became high risk due to new cancers in their families. Among high-risk survivors, 15% reported that they had never heard of BRCA testing. Of the 85% who had heard of testing, 23% reported that they had been tested.
 CONCLUSIONS: The prevalence of "high risk" cancer family histories increased by 70% in a cohort of breast cancer survivors over 7.5 years. It is important for clinicians to identify high-risk families not only at initial diagnosis, but to update the family history periodically. A substantial proportion of high-risk women had never heard of BRCA1/2 testing, and could benefit from genetic counseling to discuss the cancer risk in their families.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 1097.
Collapse
Affiliation(s)
| | | | - BA Parker
- 1 Moores UCSD Cancer Center, La Jolla, CA
| | - JP Pierce
- 1 Moores UCSD Cancer Center, La Jolla, CA
| |
Collapse
|
17
|
Madlensky L, Flatt SW, Natarajan L, Lawrence H, Nikoloff D, Fontecha M, Hao S, Hillman G, Johnson A, Parker BA, Pierce JP. Hot flashes are associated with CYP2D6 genotype in breast cancer survivors taking tamoxifen. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-6045] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #6045
Background: We have previously shown that participants in the Women's Healthy Eating and Living (WHEL) study comparison group who reported hot flashes after breast cancer treatment had more favorable disease-free survival than women who did not report hot flashes. However, this was not the case in the intervention group. The polymorphic CYP450 enzyme CYP2D6 catalyzes the conversion of tamoxifen (TAM) to one of its key active metabolites, endoxifen. Some studies have suggested that certain genetic variants of CYP2D6 are associated with a decreased likelihood of hot flashes, reduced endoxifen levels and an increased risk of disease recurrence in women receiving adjuvant TAM therapy. This analysis was performed to estimate the association between CYP2D6 genotype and hot flashes in early stage breast cancer survivors who took adjuvant TAM in the WHEL study.
 Methods: The WHEL study was a randomized trial of a dietary intervention in breast cancer survivors, who enrolled in the study within 4 years of diagnosis from 1995-2000. Participants self-reported TAM use, hot flash severity and menopausal status at study entry. Clinical characteristics (tumor stage, estrogen receptor status, chemotherapy) were extracted from medical records. Blood samples were obtained by venipuncture, separated and stored at -80 deg. DNA was extracted from stored buffy coat and analyzed using the Roche AmpliChip CYP450 Test. Women were classified according to their predicted CYP2D6 phenotype as Extensive (EM), Heterozygous Extensive (Het EM), Intermediate (IM), Poor (PM), or Ultrarapid (UM) Metabolizers.
 Results: Overall, 1434 WHEL participants had verified estrogen receptor-positive stage I or II breast cancers and reported taking TAM at baseline for at least 4 months. A total of 1411 women were successfully genotyped and their CYP2D6 phenotypes were classified as follows: 468 EM (33.2%); 665 Het EM(47.1%), 164 IM (11.6%), 86 PM (6.1%) and 28 UM (2.0%). In univariate analyses, there was a significant difference among CYP2D6 genotype in relation to hot flashes reported at baseline: 79.8% of EMs, 76.3% of Het EMs, 80.1% of IMs, 63.9% of PMs, and 75% of UMs reported hot flashes (χ2= 11.3, p=0.02). After controlling for age, menopausal status, and time since diagnosis, the PM group was half as likely to report hot flashes as the referent EM group (OR= 0.46; 95% CI= 0.28-0.78; p=0.003). Additional analyses of serum endoxifen levels and associations with disease outcome are underway.
 Conclusion: In the WHEL study, women who were classified as Poor Metabolizers of TAM, based on their CYP2D6 genotype, were half as likely as Extensive Metabolizers to report experiencing hot flashes while receiving adjuvant TAM treatment for early stage breast cancer.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 6045.
Collapse
Affiliation(s)
- L Madlensky
- 1 Moores UCSD Cancer Center, University of California San Diego, La Jolla, CA
| | - SW Flatt
- 1 Moores UCSD Cancer Center, University of California San Diego, La Jolla, CA
| | - L Natarajan
- 1 Moores UCSD Cancer Center, University of California San Diego, La Jolla, CA
| | - H Lawrence
- 2 Roche Molecular Diagnostics, Pleasanton, CA
| | - D Nikoloff
- 2 Roche Molecular Diagnostics, Pleasanton, CA
| | - M Fontecha
- 2 Roche Molecular Diagnostics, Pleasanton, CA
| | - S Hao
- 2 Roche Molecular Diagnostics, Pleasanton, CA
| | - G Hillman
- 2 Roche Molecular Diagnostics, Pleasanton, CA
| | - A Johnson
- 2 Roche Molecular Diagnostics, Pleasanton, CA
| | - BA Parker
- 1 Moores UCSD Cancer Center, University of California San Diego, La Jolla, CA
| | - JP Pierce
- 1 Moores UCSD Cancer Center, University of California San Diego, La Jolla, CA
| |
Collapse
|
18
|
Abstract
9094 Background: Studies have shown that women with breast cancer undergoing chemotherapy report disturbed sleep. Studies have also suggested that these women have very little bright light exposure, yet it is known that bright light may improve sleep. We present preliminary data from an on-going study that addresses whether bright light improves sleep in women with breast cancer undergoing chemotherapy. Methods: 11 women (mean age=50.3 yrs, SD=8.4, range: 35–70 yrs) diagnosed with stage I-III breast cancer, scheduled to receive at least 4 cycles of adjuvant anthracycline-based chemotherapy participated. Sleep quality was assessed with the Pittsburgh Sleep Quality Index (PSQI) and objective measures of sleep were assessed with 72-hours of actigraphy (Ambulatory Monitoring, Inc. and Respironics) at baseline (pre-chemotherapy) and during the last week of cycle 4 (C4). Participants were randomized into two treatment groups: bright white light (BWL; n=7) and dim red light (DRL; n=4). Both groups were instructed to self-administer light therapy for 30 minutes every morning throughout 4 cycles of chemotherapy. Results: In the BWL group, total sleep time (TST) increased by 41 min (SD=69), while wake time stayed approximately the same. In the DRL group TST decreased by 32 minutes (SD=30), while wake time increased by 27 minutes (SD=39). Subjectively, PSQI sleep latency subscale for BWL was reduced from 2.6 (SD=3.0, range=0–5) at baseline to 1.9 (SD=2.3, range=0–6) at C4, while for DRL, mean sleep latency increased from 2.7 (SD=2.5, range=0–5) at baseline to 3.0 (SD=3.0, range=0–6) at C4. PSQI total score for BWL decreased from 12.0 (SD=4.7, range=7–19) at baseline to 10.9 (SD=4.2, range=5–16) at C4 while for DRL it decreased from 8.3 (SD=3.1, range=5–11) at baseline to 7.7 (SD=5.1, range=2–12) at C4. Conclusions: Preliminary results suggest that bright white light may increase the number of hours of sleep in women undergoing chemotherapy, as well as decreasing sleep latency and improving sleep quality. As additional data are collected, we will be able to establish the significance of these effects. Supported by: CBCRP 11IB-0034, NCI CA112035, Litebook Company and the research service of the VASDHS. No significant financial relationships to disclose.
Collapse
Affiliation(s)
| | - M. Rissling
- University of California San Diego, San Diego, CA
| | | | - B. A. Parker
- University of California San Diego, San Diego, CA
| |
Collapse
|
19
|
|
20
|
Parker BA, Sturm K, MacIntosh CG, Feinle C, Horowitz M, Chapman IM. Relation between food intake and visual analogue scale ratings of appetite and other sensations in healthy older and young subjects. Eur J Clin Nutr 2004; 58:212-8. [PMID: 14749739 DOI: 10.1038/sj.ejcn.1601768] [Citation(s) in RCA: 221] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
OBJECTIVE Visual analogue scales are widely used in appetite research, yet the validity of these scales to evaluate appetite and mood has not been assessed in older subjects. The aim of this study was to determine the relations between food intake and visual analogue scale (VAS) ratings of appetite and nonappetite sensations in healthy older and young subjects. DESIGN Retrospective combined analysis of four single-blind, randomised, controlled appetite studies. SETTING All studies were conducted in the University of Adelaide, Department of Medicine, Adelaide, Australia. SUBJECTS A total of 45 healthy young men (n=24) and women (n=21) aged 18-35 y and 45 healthy older men (n=24) and women (n=21) aged 65-85 y were recruited by advertisement. INTERVENTIONS Oral, intraduodenal or intravenous administration of treatments which suppressed food intake were compared to control. Up to 90 min after treatment, a test meal was offered and subjects ate freely for between 30 and 60 min. Perceptions were assessed by 100-mm visual analogue scales administered at regular intervals. RESULTS Food intake at the test meal was positively related to perceptions of hunger, drowsiness, and calmness at both baseline and premeal (r>0.16, P<0.05), and inversely related to premeal ratings of fullness (r> 0.2, P<0.05) in both older and young subjects. Food intake was related to VAS ratings at least as strongly, if not more so, in older as in young subjects. CONCLUSIONS These observations (i) confirm that food intake is related to perceptions of hunger and fullness as assessed by VAS in healthy older and young subjects, and (ii) suggest that sensations, not obviously associated with appetite, including 'drowsiness' and 'calmness', are also associated with food intake.
Collapse
Affiliation(s)
- B A Parker
- Department of Medicine, University of Adelaide, Royal Adelaide Hospital, North Terrace, Adelaide, South Australia, Australia
| | | | | | | | | | | |
Collapse
|
21
|
|
22
|
Bartlett NL, Petroni GR, Parker BA, Wagner ND, Gockerman JP, Omura GA, Canellos GP, Robert M, Johnson JL, Peterson BA. Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854. Cancer 2001; 92:207-17. [PMID: 11466671 DOI: 10.1002/1097-0142(20010715)92:2<207::aid-cncr1311>3.0.co;2-d] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND To address the feasibility and outcome of moderate dose intensification with granulocyte-colony stimulating factor (G-CSF) for patients with aggressive non-Hodgkin lymphoma (NHL), the Cancer and Leukemia Group B (CALGB) conducted two studies evaluating dose-escalated cyclophosphamide and etoposide in the cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide (CHOPE) regimen. METHODS Eligibility criteria included histologically documented, diffuse small cleaved, diffuse mixed, diffuse large cell, or immunoblastic lymphoma, Stage III--IV or bulky Stage II disease, and an ECOG performance status of 0--1. CALGB 8852, a group-wide study, accrued 227 patients: 120 patients in the pilot study to determine the maximum tolerated dose (MTD) without G-CSF and 107 in the pilot study of dose-escalated CHOPE with G-CSF. CALGB 8854, a limited-institution, Phase I study, enrolled 38 patients and determined the MTD of CHOPE with G-CSF to be used in CALGB 8852. The MTD in both studies was defined as the dose at which 50% of patients had 1) Grade 4 neutropenia or thrombocytopenia lasting 7 days or more, or 2) Grade 3--4 hemorrhage or nonhematologic toxicity (excluding alopecia, nausea, and emesis), or 3) were prevented from receiving 100% of drug on Day 22. RESULTS The MTD of CHOPE without G-CSF was cyclophosphamide 1000 mg/m(2) on Day 1 and etoposide 100 mg/m(2) on Days 1--3 with doxorubicin 50 mg/m(2) on Day 1, vincristine 1.4 mg/m(2) (maximum, 2 mg) on Day 1, and prednisone 100 mg on Days 1--5. With the addition of G-CSF at 200 microg/m(2) on Days 5--19, the MTD was cyclophosphamide 1500 mg/m(2) and etoposide 160 mg/m(2) on Days 1-3 with standard doses of doxorubicin, vincristine, and prednisone. Increasing the dose of G-CSF from 200 microg/m(2) to 400 microg/m(2) did not allow for further dose escalation. The primary toxicity in all cohorts was neutropenia. Four toxic deaths occurred on CALGB 8852. The 5-year failure free survival (FFS) and overall survival (OS) rates for eligible patients on CALGB 8852 were 31% (95% confidence interval [95%CI], 23--39) and 48% (95%CI, 40--57), respectively. The 5-year FFS and OS rates for eligible patients on CALGB 8854 were 34% (95%CI, 17--52) and 51% (95%CI, 33--70), respectively. CONCLUSIONS Moderate dose escalation with G-CSF is feasible. However, response and survival rates of patients who receive dose-escalated CHOPE, even with the addition of G-CSF, appear similar to the rates reported with standard-dose CHOP.
Collapse
MESH Headings
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols/administration & dosage
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Cyclophosphamide/administration & dosage
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Doxorubicin/administration & dosage
- Etoposide/administration & dosage
- Female
- Granulocyte Colony-Stimulating Factor/administration & dosage
- Humans
- Lymphoma, Large B-Cell, Diffuse/drug therapy
- Lymphoma, Large B-Cell, Diffuse/pathology
- Lymphoma, Large-Cell, Immunoblastic/drug therapy
- Lymphoma, Large-Cell, Immunoblastic/pathology
- Lymphoma, Non-Hodgkin/drug therapy
- Lymphoma, Non-Hodgkin/pathology
- Male
- Middle Aged
- Neutropenia/chemically induced
- Neutropenia/prevention & control
- Prednisone/administration & dosage
- Treatment Outcome
- Vincristine/administration & dosage
Collapse
Affiliation(s)
- N L Bartlett
- Washington University School of Medicine, St. Louis, Missouri, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Christian TJ, Manley-Harris M, Field RJ, Parker BA. Kinetics of formation of Di-D-fructose dianhydrides during thermal treatment of inulin. J Agric Food Chem 2000; 48:1823-1837. [PMID: 10820101 DOI: 10.1021/jf9911186] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
Thermal treatments of solid mixtures of inulin and citric acid result in the formation of di-D-fructose dianhydrides and oligomers derived therefrom. The kinetics of formation of these compounds have been investigated and simulated in computer studies. A mechanism is proposed. The conditions used in this study were analogous to the conditions pertaining to the roasting of chicory, during which similar compounds are formed.
Collapse
Affiliation(s)
- T J Christian
- Shafizadeh Center, University of Montana, Missoula, Montana 59812, USA
| | | | | | | |
Collapse
|
24
|
Soignet SL, Miller VA, Pfister DG, Bienvenu BJ, Ho R, Parker BA, Amyotte SA, Cato A, Warrell RP. Initial clinical trial of a high-affinity retinoic acid receptor ligand (LGD1550). Clin Cancer Res 2000; 6:1731-5. [PMID: 10815891] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
Retinoids mediate their biological response by binding to specific nuclear receptors, including retinoic acid receptors and/or retinoid X receptors. LGD1550 is a high-affinity ligand for all three retinoic acid receptors (alpha, beta, and gamma isoforms) and a potent inhibitor of AP-1, a protein that is closely linked with trophic responses and malignant transformation. We conducted a dose ranging study to evaluate the pharmacokinetics, safety, clinical tolerance, and potential efficacy of this drug in patients with advanced cancer. Twenty-seven patients received oral doses of LGD1550 once per day at doses ranging from 20-400 microg/m2. Skin toxicity was the dose-limiting reaction at the 400 microg/m2 daily dose level. Less prominent reactions included nausea and headache. No major antitumor effects were observed. Pharmacokinetic studies in 15 patients at five dose levels showed that the peak plasma concentration (Cmax) and areas under the plasma concentration-time curve on day 1 were dose-proportional and were similar to values obtained on days 15, 29, and 84. Unlike other retinoids, LGD1550 did not induce its own metabolism, and there was little evidence of drug accumulation. The t1/2 was approximately 5 h after both the initial and repeated doses. We conclude that once-daily doses of LGD1550 of up to 300 microg/m2 are relatively well tolerated. Additional clinical explorations are warranted, especially in patients with cancers of the prostate, thyroid, head and neck, and cervix.
Collapse
Affiliation(s)
- S L Soignet
- Department of Medicine, Memorial Sloan-Kettering Cancer Center, Cornell University Medical College, New York, New York 10021, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Soignet SL, Benedetti F, Fleischauer A, Parker BA, Truglia JA, Ra Crisp M, Warrell RP. Clinical study of 9-cis retinoic acid (LGD1057) in acute promyelocytic leukemia. Leukemia 1998; 12:1518-21. [PMID: 9766493 DOI: 10.1038/sj.leu.2401150] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The use of all-trans retinoic acid (RA) for remission induction markedly increases survival of patients with acute promyelocytic leukemia (APL) compared to patients treated solely with cytotoxic chemotherapy. However, clinical resistance to this agent develops rapidly, which has been associated with a progressive decline in plasma drug concentrations. Previous studies suggested that 9-cis RA, a retinoid receptor 'pan agonist' did not induce its own catabolism to the same extent as all-trans RA. Therefore, we conducted a dose-ranging study of this compound in patients with both relapsed and newly diagnosed APL. We treated 18 patients with morphologically diagnosed APL (13 relapsed, five newly diagnosed). The daily dose of 9-cis RA ranged from 30 to 230 mg/m2/day given as a single oral dose. Four of 12 (33%) relapsed patients (three of whom were previously treated with all-trans RA) and four of five (80%) newly diagnosed patients achieved complete remission. The sole failure in the newly diagnosed group died early from an intracranial hemorrhage. One other patient with t(9;12) translocation had substantial hematologic improvement. The drug was generally well tolerated; headache and dry skin were the most common adverse reactions. Three patients were treated with corticosteroids for signs of incipient 'RA syndrome.' These preliminary data suggest that 9-cis RA is an effective agent for remission induction and deserves further investigation in patients with retinoid-sensitive APL.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Alitretinoin
- Antineoplastic Agents/adverse effects
- Antineoplastic Agents/therapeutic use
- Child
- Child, Preschool
- Chromosomes, Human, Pair 12
- Chromosomes, Human, Pair 9
- Dose-Response Relationship, Drug
- Female
- Humans
- Infant
- Leukemia, Promyelocytic, Acute/blood
- Leukemia, Promyelocytic, Acute/drug therapy
- Leukemia, Promyelocytic, Acute/genetics
- Leukocyte Count/drug effects
- Male
- Middle Aged
- Platelet Count/drug effects
- Recurrence
- Translocation, Genetic
- Tretinoin/adverse effects
- Tretinoin/therapeutic use
Collapse
Affiliation(s)
- S L Soignet
- Department of Medicine, Memorial Sloan-Kettering Cancer Center, and the Cornell University Medical College, New York, NY 10021, USA
| | | | | | | | | | | | | |
Collapse
|
26
|
Paulson TG, Wright FA, Parker BA, Russack V, Wahl GM. Microsatellite instability correlates with reduced survival and poor disease prognosis in breast cancer. Cancer Res 1996; 56:4021-6. [PMID: 8752173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Size changes in microsatellite sequences have been detected in many types of cancer, but the influence of this form of genetic instability on disease progression remains unclear. We determined the incidence of microsatellite instability in breast cancer by comparing PCR-amplified sequences from paraffin-embedded samples of normal and tumor tissue from affected individuals. This analysis showed that at least 30% of breast cancers exhibit microsatellite instability (MI). Of importance, MI correlated with indicators commonly associated with poor disease prognosis, including lymph node status, tumor size, and advanced tumor stage. Individuals with MI+ tumors also showed significantly reduced disease-free and overall survival. These data contrast with studies showing that MI correlates with improved prognosis in colon and gastric cancers. We propose that defects resulting in MI promote disease progression and result in a poor prognosis in breast cancer.
Collapse
Affiliation(s)
- T G Paulson
- Department of Biology, University of California, San Diego, La Jolla 92037, USA
| | | | | | | | | |
Collapse
|
27
|
White CA, Halpern SE, Parker BA, Miller RA, Hupf HB, Shawler DL, Collins HA, Royston I. Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 90 anti-idiotype monoclonal antibodies. Blood 1996; 87:3640-9. [PMID: 8611688] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
Tumor-specific anti-idiotype (anti-Id) monoclonal antibodies (MoAbs) to B-cell lymphomas have been administered to patients, resulting in significant clinical responses. However, clinical responses have been limited by the emergence of Id-negative lymphoma. To overcome the problem of tumor heterogeneity, we conducted a pilot evaluation of the safety and effectiveness of yttrium 90 (90Y)-labeled anti-Id and shared Id (sId) MoAbs in non-Hodgkin's B-cell lymphoma. Nine patients with relapsed B-cell lymphoma in whom tumor was successfully targeted with 111In-labeled anti-Id MoAb were treated with 90Y-labeled anti-Id MoAb. A total of 19 courses (one to four per patient) were administered using 1,000 to 2,320 mg unlabeled clearing MoAb and 10 to 54 mCi 90Y MoAb per patient. Two of nine patients had a complete response, one a partial response, three stable disease, and three disease progression. Time to progression varied from 1 to 12 months. Toxicities were predominately hematologic, and only one patient developed infection and required transfusion. At progression, three of five assessable patients had Id-positive lymphoma and two had Id-negative lymphoma. Human antimouse antibodies (HAMA) did not develop in the patients after treatment. 90Y anti-Id MoAbs demonstrated excellent in vivo stability, produced significantly tumor regression in three of nine patients, exhibited acceptable toxicities, and elicited no HAMA formation. Further investigation of repetitive, low-dose 90Y anti-Id and MoAb therapy is warranted; however, the advantages of a pan B MoAb may prove the latter to be the agent of choice for the radio immunotherapy of B-cell lymphoma.
Collapse
Affiliation(s)
- C A White
- Sidney Kimmel Cancer Center, Sharp HealthCare, San Diego, CA 92121, USA
| | | | | | | | | | | | | | | |
Collapse
|
28
|
Choi WS, Parker BA, Pierce JP, Greenberg ER. Regional differences in the incidence and treatment of carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 1996; 5:317-20. [PMID: 8722225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
Greater use of mammography in the United States in recent years has increased the detection of early neoplasms of the breast, including carcinoma in situ. However, the occurrence and treatment of diagnosed carcinoma in situ of the breast has not been fully described. Our goal was to examine temporal, geographic, and demographic patterns in the incidence and treatment of in situ breast cancer. The study included data from all women with in situ breast cancer that had been detected in the nine Surveillance, Epidemiology, and End Results areas of the United States from 1975 through 1990 (Surveillance Program, Cancer Statistics Branch, Bethesda, MD: National Cancer Institute, November, 1993). We calculated age-adjusted incidence rates (1970 United States standard) using data on histology and treatment from the Surveillance, Epidemiology, and End Results data tape. We assessed predictors of treatment by mastectomy using multiple logistic regression. From 1975-1979 to 1986-1990, the age-adjusted incidence rate of in situ breast cancer increased from 4.7 to 16.9/100,000 women. The increase occurred in all age groups and among both white and black women. However, there was nearly a 2-fold difference in incidence rates across geographic areas in 1986-1990, ranging from < 12/100,000 in Iowa and New Mexico to > 20/100,000 in San Francisco and Seattle. Geographic variability in treatment was also evident, with mastectomy, rather than breast-conserving therapy, performed on 46% of the women with in situ breast cancer in San Francisco and on 66% of those in Iowa. The incidence of diagnosed in situ breast cancer increased markedly during the 1980s, and there was substantial geographic variability in the rates of detection of these tumors and in the type of therapy received. Although mastectomy became a less common treatment over time, it was still performed on a high proportion of women with in situ breast cancer during the latter part of the decade.
Collapse
Affiliation(s)
- W S Choi
- Cancer Prevention and Control Program, University of California, San Diego, La Jolla 92093-0901, USA
| | | | | | | |
Collapse
|
29
|
Sullivan RM, Parker BA, Szechtman H. Role of the corpus callosum in expression of behavioral asymmetries induced by a unilateral dopamine lesion of the substantia nigra in the rat. Brain Res 1993; 609:347-50. [PMID: 8508317 DOI: 10.1016/0006-8993(93)90895-t] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The present study examines the effects of sectioning the corpus callosum on the expression of asymmetric behaviors induced by a unilateral 6-hydroxydopamine (6-OHDA) lesion of the substantial nigra. Severing the corpus callosum eliminated the asymmetry in spontaneous investigation of edges in an open-field, without affecting total time of investigation. In contrast, callosotomy reduced the magnitude of externally cued turning, but failed to affect the directional distribution of responding. Moreover, it reduced the magnitude of apomorphine- but not amphetamine-induced turning. It is suggested that transcallosal communication is required for those behavioral asymmetries induced by a unilateral dopamine lesion which depend on head, rather than whole body movements.
Collapse
Affiliation(s)
- R M Sullivan
- Department of Biomedical Sciences, McMaster University, Hamilton, Ont., Canada
| | | | | |
Collapse
|
30
|
Abstract
1. Families of persons with severe mental illness are often anguished because of stressors and are unprepared to be caregivers. Their needs must be addressed by mental health professionals. 2. Family members may experience grief, guilt, anger, powerlessness, and fear. 3. Education and peer groups may be most helpful to family members in dealing with their distress and becoming better prepared caregivers.
Collapse
Affiliation(s)
- B A Parker
- Augusta Alliance for the Mentally Ill, Georgia
| |
Collapse
|
31
|
Parker BA, Santarelli M, Green MR, Anderson JR, Cooper MR, Case D, Barcos M, Peterson BA, Gottlieb AJ. AMOPLACE treatment of intermediate-grade and high-grade malignant lymphoma: a Cancer and Leukemia Group B study. J Clin Oncol 1993; 11:248-54. [PMID: 8426201 DOI: 10.1200/jco.1993.11.2.248] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
PURPOSE In an attempt to improve the efficacy of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphomas, a phase II evaluation of a regimen consisting of Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), methotrexate, Oncovin (vincristine; Eli Lilly Co, Indianapolis, IN), prednisone, leucovorin, cytarabine (ara-c), cyclophosphamide, and etoposide (AMOPLACE) was conducted. This regimen includes three additional agents not found in CHOP, uses weekly doses of alternating myelosuppressive and nonmyelosuppressive drugs, and incorporates most single agents active against diffuse lymphomas. PATIENTS AND METHODS Ninety-one previously untreated patients were enrolled and 60 patients were confirmed eligible after central pathology review. Fifty-eight percent of patients had diffuse large-cell lymphoma (DLCL), 83% had stage III or IV disease, and 45% had B symptoms. RESULTS Patients were treated with six to eight cycles of AMOPLACE and analyzed for response and survival. With a median follow-up of 48 months, complete responses (CRs) were seen in 68% of all patients with failure-free survival (FFS) and overall survival (OS) estimates at 4 years of 45% and 54%. In the DLCL subset, the CR rate was 69% and FFS and OS estimates at 4 years were 49% and 60%, respectively. The major toxicity was myelosuppression, with 73% of patients having WBC nadirs less than 1,000/microL; two treatment-related deaths occurred. CONCLUSION We conclude that AMOPLACE is associated with CR and OS rates comparable with those of other third-generation regimens.
Collapse
Affiliation(s)
- B A Parker
- University of California, San Diego Cancer Center 92103-8421
| | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Parker BA. When your medical/surgical patient is also mentally ill. Nursing 1992; 22:66-8. [PMID: 1584498 DOI: 10.1097/00152193-199205000-00017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
33
|
Parker BA, Vassos AB, Halpern SE, Miller RA, Hupf H, Amox DG, Simoni JL, Starr RJ, Green MR, Royston I. Radioimmunotherapy of human B-cell lymphoma with 90Y-conjugated antiidiotype monoclonal antibody. Cancer Res 1990; 50:1022s-1028s. [PMID: 2297715] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
We report the first case of 90Y-conjugated monoclonal antibody (MoAb) administration for human radioimmunotherapy. Ten mCi 90Y-labeled antiidiotype (anti-Id) MoAb were administered to a patient with B-cell lymphoma whose tumor successfully imaged with 111In-labeled anti-Id MoAb. No significant toxicities were observed. More than 2 g of unlabeled anti-Id MoAb were administered while clearing the circulating IgM idiotype prior to administration of the 90Y-MoAb. Transient partial regression of disease was observed. Serial fine needle aspirations of a malignant lymph node documented in vivo anti-Id penetration into a site that did not image by radioimmunoscintigraphy. The radiosensitivity of B-cell lymphoma, the tumor specificity of anti-Id, the antitumor activity of anti-Id alone, and the safe administration of 10 mCi 90Y-labeled anti-Id MoAb in this report suggest further investigation of this radioimmunoconjugate for therapy of B-cell lymphoma is warranted.
Collapse
Affiliation(s)
- B A Parker
- University of California, San Diego Cancer Center 92103
| | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Abstract
Severe hyperphosphatemia and hypocalcemia developed following the administration of a single hypertonic sodium phosphate enema in an adult with mild chronic renal insufficiency.
Collapse
|
35
|
Hatoff DE, Gertler SL, Miyai K, Parker BA, Weiss JB. Hypervitaminosis A unmasked by acute viral hepatitis. Gastroenterology 1982; 82:124-8. [PMID: 7198070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/02/2022]
Abstract
A case of acute hypervitaminosis A complicating viral hepatitis is reported. Twenty days after presenting with hepatitis B, a 42-yr-old vegetarian developed acute hypervitaminosis A in the absence of recent, massive exposure to the vitamin. Findings included headache, confusion, skin desquamation, and hypercalcemia. Prior to developing hepatitis, he had ingested supplemental vitamin A without recognized ill effect. Liver and serum vitamin A without recognized ill effect. Liver and serum vitamin A levels were both elevated; the liver biopsy showed abundant, lipid-filled Ito cells and perisinusoidal fibrosis. This case demonstrates that patients with excessive hepatic stores of vitamin A may develop hypervitaminosis A during acute, intercurrent liver disease. Levels of retinol binding protein are reduced in hepatitis. This phenomenon may account for the findings in this case, since vitamin A is more toxic when not specifically bound to retinol binding protein. The size of the population at risk for this complication of hepatitis in unknown, but presumably it is growing with the widespread use of supplemental vitamin A.
Collapse
|
36
|
|
37
|
Parker BA, Stark GR. Regulation of simian virus 40 transcription: sensitive analysis of the RNA species present early in infections by virus or viral DNA. J Virol 1979; 31:360-9. [PMID: 225559 PMCID: PMC353458 DOI: 10.1128/jvi.31.2.360-369.1979] [Citation(s) in RCA: 571] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
We have examined the discrete species of simian virus 40 (SV40) RNA present very early in infection of monkey cells with wild-type virus, with mutant tsA58 virus, and with the corresponding DNAs to distinguish between two classes of models for control of late transcription: (i) positive control mediated by large-T antigen and (ii) negative control mediated by a repressor protein associated with viral DNA in the virion. Total cytoplasmic or nuclear polyadenylated RNAs from infected cells were denatured with glyoxal, separated by electrophoresis on agarose gels, and transferred to diazobenzyloxymethyl paper. The positions of specific early and late RNA species were determined with region-specific SV40 DNA probes. The technique can detect individual RNAs present at the level of less than one copy per cell. After 9.5 h at 37 degrees C, appreciable amounts of two early RNAs (2.6 kilobases [kb] and 2.9 kb) were present in the cytoplasm of cells infected with wild-type virus or DNA, along with much smaller amounts of two late RNAs, 1.6 kb (16S) and 2.5 kb (19S). The amounts of the late RNAs were reduced, but they were still synthesized in the presence of cytosine arabinoside, an inhibitor of DNA synthesis. In comparable infections with tsA58 virus or DNA at nonpermissive temperature (41 degrees C), substantial amounts of the two early RNAs were again present, but the two late RNAs could not be detected. However, small amounts of the late RNAs were found when infections with tsA58 virus or DNA were prolonged to 30 h at 41 degrees C. These results are not consistent with negative control of late transcription through the action of a repressor and, taken together with other data, suggest that T antigen has an active role in late RNA synthesis. Specific early and late viral RNAs were also detected in the nuclear poly(A)(+) fractions and were similar in size to the RNA species found in the cytoplasmic polyadenylated fractions. The late nuclear RNAs (1.8 and 2.9 kb) were significantly larger than the late cytoplasmic species, possibly because they are precursors. The 2.6- and 2.9-kb early RNAs found in the cytoplasm are probably the messengers for large-T and small-t antigens, respectively.
Collapse
|
38
|
Alwine JC, Kemp DJ, Parker BA, Reiser J, Renart J, Stark GR, Wahl GM. Detection of specific RNAs or specific fragments of DNA by fractionation in gels and transfer to diazobenzyloxymethyl paper. Methods Enzymol 1979; 68:220-42. [PMID: 94421 DOI: 10.1016/0076-6879(79)68017-5] [Citation(s) in RCA: 467] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
39
|
|